Servier completes the acquisition of Day One Biopharmaceuticals
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in pediatric low-grade glioma.
DAWN - Day One Biopharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.50
DETAILS
HIGH:
$21.50
LOW:
$21.50
MEDIAN:
$21.50
CONSENSUS:
$21.50
DOWNSIDE:
0.14%
Stock News
Servier completes the acquisition of Day One Biopharmaceuticals
/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender
Servier finalise l'acquisition de Day One Biopharmaceuticals
/PRNewswire/ -- Servier, un groupe pharmaceutique international indépendant gouverné par une fondation, a annoncé ce jour avoir finalisé avec succès son offre
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High – What’s Next?
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday. The company traded as high as $21.47 and last traded at $21.46, with a volume of 904610 shares traded. The stock had previously closed at $21.45. Analysts Set New Price Targets A number of
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More
Pre-Market Stock Futures: Futures are trading lower as we hit the mid-point of the trading week, and while we didn't see the snapback rally that was the star of the show Monday, at least all four major indices held their own as the conflict in Iran grinds on. The Nasdaq was able to eke out... Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More.
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen
Day One Biopharmaceuticals (NASDAQ: DAWN) executives highlighted accelerating commercial momentum for OJEMDA and outlined multiple upcoming clinical catalysts during a fireside chat at TD Cowen's 46th Annual Healthcare Conference. Charles York, the company's CFO and COO, said 2025 marked a "fantastic year" for Day One as it delivered its first full year of OJEMDA sales following
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday. That was the biggest spike in oil pricing since 2020. With the retreat in the black gold, the major indices did a massive... Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims and Hers, Intuit, Lowe's, Qualcomm, Rivian, Strategy and More.
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
Stock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East Tensions
The S&P 500 (^GSPC 1.33%) fell 1.33% to 6,740.02, the Nasdaq Composite (^IXIC 1.59%) slid 1.59% to 22,387.68, and the Dow Jones Industrial Average (^DJI 0.95%) dropped 0.95% to 47,501.55 as a weak jobs report and surging oil reinforced risk-off sentiment.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Servier for $21.50 per share in an all-cash transaction, representing a total equity value of approximately $2.5 billion. The investigation concerns whether the Day One Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Servier. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)
NEW YORK, March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) related to its sale to Servier Pharmaceuticals LLC.
DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) to Servier for $21.50 per share in cash. Halper Sadeh encourages Day One shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Day One and its board of directors viola.
Day One Shares Surge After $2.5B Servier Deal
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares are trading higher Friday after the company announced that Servier will acquire it for $21.50 per share in cash.
Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion
Independent international pharmaceutical group Servier will buy Day One Biopharmaceuticals for a total equity value of about $2.5 billion, the companies said on Friday.
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
SURESNES, France and BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.
Price Targets
H.C. Wainwright Downgrades Day One Biopharmaceuticals (DAWN) to Neutral
$21.50
(was $21.36)
Andrew Maldonado
·
H.C. Wainwright
Day One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler
$26.00
(was $8.28)
Piper Sandler
Day One Biopharmaceuticals upgraded to Buy from Underperform at BofA
$24.00
(was $14.31)
Alec Stranahan
·
Bank of America Securities
Day One Biopharmaceuticals (DAWN) PT Lowered to $40 at H.C. Wainwright
$40.00
(was $16.60)
Andrew Maldonado
·
H.C. Wainwright
Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
$45.00
(was $21.34)
Joseph Catanzaro
·
Piper Sandler
HC Wainwright & Co. Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $35
$35.00
(was $21.61)
H.C. Wainwright
Needham Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $40
$40.00
(was $20.53)
Needham
Goldman Sachs Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $45
$45.00
(was $21.74)
Goldman Sachs
Day One Biopharmaceuticals price target raised to $40 from $35 at Piper Sandler
$40.00
(was $15.79)
Joseph Catanzaro
·
Piper Sandler